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Abstract 
Cancer is a disease the humans has been trying to eradicate for hundred of years. This 
disease, caused by the abnormal replication of various cells in our body, can cause a multitude of 
complications ranging anywhere from hormone imbalances all the way to physical obstructions 
of organs and organ systems. As technology begins to advance and the methods which determine 
how we detect, treat, and prevent cancer advance with it, it becomes possible to specify what 
kind of tumor the screening is being done for (benign versus cancerous) and the specific type of 
tumor it is in relation to its location and stage of maturation. One of the techniques which is 
making this degree of specificity possible is liquid biopsy which, if perfected, will provide a 
number of other innovate benefits for patients looking for tumor biopsies, specifically within the 
context of pancreatic cancer. If liquid biopsy were able to be used reliably in a clinical setting, 
patients would no longer have to undergo invasive procedures like surgical biopsy, and their 
progress through treatment would be more closely monitored and more accurate than ever 
before.   
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Pancreatic cancer is a condition which has plagued the US since the 18th century. The 
American Cancer Society predicts that 56,770 people will be diagnosed with pancreatic cancer in 
2019 alone, and of those 56,770 individuals, 45,750 of them will die. More than 7% of all cancer 
deaths are attributable to pancreatic cancer and there are a number of reasons as to why, 
specifically linked to its detection and diagnosis. Due to the pancreas being located deep within 
the abdominal cavity, it is hard to locate the tumor with the naked eye, and even during a 
physical exam. Additionally, symptoms of Pancreatic Cancer are not always obvious and slowly 
begin to manifest themselves over time. Lastly, there are no proven biomarkers to help doctors 
diagnose the disease in its early stages and as a result, most pancreatic cancers are not detected 
until stage IV, which in many cases may be too late. However, the issue does not stop there. In 
addition to the clinical difficulty associated with this particular form of cancer comes the 
difficulty experienced by the patient when it comes to traditional methods of pancreatic cancer 
biopsy and detection. 
Traditionally, pancreatic cancer is diagnosed in what can be considered a three step 
process. First, various imaging is performed on the abdominal region of the patient to detect any 
sign of tumor formation. If there is evidence of a tumor present, many times the doctor will have 
the patient undergo a biopsy to determine whether or not the tumor is benign or cancerous. 
Traditional method of cancer biopsy, especially in a region located deep within the abdomen, is 
performed using one of three methods. The first of these methods is percutaneous biopsy, where 
a needle is inserted through the abdomen and into the pancreas, where a fine needle aspiration is 
performed. The second of these methods is an endoscopic biopsy, in which the physician passes 
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an endoscope down the throat of a patient and into the small intestine if the patient near the 
pancreas. From there, a fine needle aspiration or cell removal is performed on the tumor to obtain 
material for analysis. The last method used is a surgical biopsy. During a surgical biopsy, a 
laparoscopic surgery is performed, and the surgeon takes samples from all tissue on or around 
the pancreas so that they can be sent for biopsy. Each  of these methods is not only expensive, 
ranging anywhere from $800 to a couple of thousand of dollars, but they are all considerably 
invasive and must be performed under anesthesia. However, there has been a new method of 
biopsy, known as liquid biopsy,  which has been introduced to the scientific community. If made 
to be reliable, it may drastically change the way and the speed in which cancer, and pancreatic 
cancer in particular can be recognized and diagnosed. 
Liquid biopsy is a test done to look for cancer cells or tiny fragments of circulating tumor 
DNA (ctDNA) that may be found in the blood of an at-risk patient.Through this process, it is 
possible to gather data about the cancer and its origins, and use this data to collect a variety of 
information that could be pivotal in the treatment of the cancer. First, once the ctDNA is 
obtained, it can be analyzed to specify the location mutation responsible for the appearance of 
the tumor. By doing this, physicians will be able to deduce which method of treatment will be 
most effective in the eradication of the cancer. Second, physicians can track the progression of 
the cancer and take note of how exactly it is responding to treatment. Not only will it be 
significantly cheaper and efficient to observe the cancer as often as needed, but monitoring the 
exact amount of ctDNA present will in the blood will also be a reliable indicator of whether or 
not the cancer is growing, shrinking or remaining the same.  Lastly, this procedure will have a 
significant role in the early recognition of whether or not a cancer is in remission or recurrence. 
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In order to do this, patients may come in on a consistent basis to have their ctDNA levels 
checked, and if any trace of ctDNA is found in the patient’s blood sample, their physician can be 
informed as soon as possible, increasing the chances of providing effective and timely care for 
these patients. Numerous studies have been performed to investigate the practicality and 
reliability of this new form of biopsy in a clinical setting, and there has been one type of cancer 
in particular for which the results appear to be especially significant - and that is pancreatic 
cancer. 
The key to making liquid biopsy an effective tool in a clinical setting is not only the 
discovery of specific biomarkers which can serve as tumor identifiers, but also studying these 
biomarkers to figure out the specific information they give us regarding the nature and location 
of a tumor. Exosomes, which are membrane vesicles that are released from a wide range of cells 
including cancer cells, are one of such biomarkers which is proving to be a viable candidate in 
regards to the detection and analysis of pancreatic cancer. Due to their role in the formation of 
cellular environments and their wide array of possible interactions with target genes, miRNA 
expression profiles of these vesicles gives them tremendous potential to be biomarkers for 
cancers and their progression (). Another potential biomarker which is currently being 
investigated are circulating tumor cells, otherwise known as CTCs. While these cells are rare in 
the blood, the number of CTCs in the blood of a cancer patient is believed to be correlated with 
tumor development, treatment response, tumor recurrence, and long-term prognosis for many 
cancers. However, while this may prove to be in important component in liquid biopsy, its 
implications regarding pancreatic cancer in particular are unclear and thus require further 
evaluation. The last potential biomarkers which are being targeted in the investigation of liquid 
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biopsy are cell-free nucleic acids (cfNA). These cfNAs contain information that can be used to 
detect tumors, reflect tumor burden, and monitor response to therapies. cfNAs are also useful in 
the sense that they are found in abundance in the blood, making them easy to collect and analyze 
(). 
When it comes to pancreatic cancer, all of these biomarkers have shown significant 
results in regards to the early and differential diagnosis of the disease. For example, in a study 
performed by Dr, Zi-Hao Qi and his team, it was observed that CTCs were located in the blood 
of subjects who had Pancreatic Ductal Adenocarcinomas, but no CTCs were detected in the 
blood of healthy donors. They also served as sufficient monitoring sources for treatment efficacy 
in pancreatic cancer patients.  Additionally, they found that miRNA, a significant part of cfNAs, 
was a “sensitive and specific body fluid based biomarker” for pancreatic cancer. Not only could 
miRNAs be used as a method of early diagnosis for pancreatic cancer, but they could also help 
with differential diagnosis, indicating whether the tumor was benign or malignant, and the 
progressive extent of invasiveness. As for exosomes, the genomic DNA extracted from these 
vesicles has been used to determine DNA mutations for cancer diagnoses. They can also be used 
to measure a protein known as GPC1, which can distinguish between stage I-IV pancreatic 
cancer as compared to healthy individuals (). 
In the future, liquid biopsy has an increasing potential to serve as a less invasive tool for 
cancer diagnosis, prognosis, and treatment markers. From using exosomes to evaluate the DNA 
composition of potential carcinomas to using CTCs to monitor and manage cancer treatment, this 
new form of biopsy could pave the way in terms of ease and efficiency for cancer diagnosis and 
treatment as we know it. However, the process is by no means perfect, and in the future, there are 
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many advancements which must be made before liquid biopsy will be an efficient tool in the 
clinical setting. For starters, liquid biopsy is still proving to have a lower sensitivity and 
specificity than when compared to its traditional alternatives. This is because when taking a 
blood sample for liquid biopsy, you are looking for significant chances in the composition of the 
bodily fluid, rather than taking a sample directly from the tumor itself. If the change in the bodily 
fluid composition is not significant enough to warn a physician of potential, growing, or 
resurfacing carcinomas, they may miss something that would not have been overlooked using 
traditional biopsy methods. The other big limitation of liquid biopsy is the reliability of the blood 
samples. As previously mentioned, CTCs are fairly rare in the blood, and there has not been a 
method of ctDNA isolation and analysis which has proven sufficiently reliable to date (). Once 
these issues have been adequately solved and implemented, there is no doubt that liquid biopsy 
will bring revolutionary change in the ways with which we detect, target, and eradicate cancer 
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